ReviewHuman vaccines2010
Development of a Chlamydia trachomatis T cell Vaccine.
Review in Human vaccines, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Simultaneous Intramuscular And Intranasal Administration Of Chitosan Nanoparticles-AdjuvantedInternational journal of nanomedicine · 2019Article
- In silico prediction of T- and B-cell epitopes in PmpD: First step towards to the design of a Chlamydia trachomatis vaccine.Biomedical journal · 2018Article
- Identification of MHC-Bound Peptides from Dendritic Cells Infected with Salmonella enterica Strain SL1344: Implications for a Nontyphoidal Salmonella Vaccine.Journal of proteome research · 2017Article
- Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.Expert review of vaccines · 2016Review
- Activation of the NLRP3 inflammasome by vault nanoparticles expressing a chlamydial epitope.Vaccine · 2015Article
- Bioinformatic Analysis of Chlamydia trachomatis Polymorphic Membrane Proteins PmpE, PmpF, PmpG and PmpH as Potential Vaccine Antigens.PloS one · 2015Article
- T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice.Nanomedicine : nanotechnology, biology, and medicine · 2014Article
- Review
- Chlamydia trachomatis-infected epithelial cells and fibroblasts retain the ability to express surface-presented major histocompatibility complex class I molecules.Infection and immunity · 2014Article
- Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.Frontiers in cellular and infection microbiology · 2013Review
- Formulation, characterization, and expression of a recombinant MOMP Chlamydia trachomatis DNA vaccine encapsulated in chitosan nanoparticles.International journal of nanomedicine · 2013Article
- Proteomic identification of immunodominant chlamydial antigens in a mouse model.Journal of proteomics · 2012Article
- CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Immunity and vaccines against sexually transmitted Chlamydia trachomatis infection.Current opinion in infectious diseases · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
The immune correlates of protection for most of the currently used vaccines are based on long-lived humoral immunity. Vaccines based on humoral immunity alone are unlikely to protect against infections caused by intracellular pathogens and today's most pressing infectious diseases of public health importance are caused by intracellular infections that not only include Chlamydia trachomatis but also tuberculosis, malaria, and HIV/AIDS. For these infections, vaccines that induce cellular immune responses are essential. Major impediments in developing such vaccines include difficulty in identifying relevant T cell antigens and delivering them in ways that elicit protective cellular immunity. In turn this is compounded by the complexity and plasticity of T cell developmental pathways that often correlate with specific aspects of protective immunity. Genomics and proteomics now provide tools to allow unbiased selection of candidate T cell antigens. This review mainly focuses on an immunoproteomic approach used in our laboratory to identify Chlamydia T cell antigens and how these T cell antigens can be developed into a future human Chlamydia vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.